Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) Income from Continuing Operations (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Income from Continuing Operations for 4 consecutive years, with 11146000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 52.69% to 11146000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 35466000.0 through Dec 2025, up 33.13% year-over-year, with the annual reading at 35466000.0 for FY2025, 33.13% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 11146000.0 at Spruce Biosciences, down from 8212000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2067000.0 in Q2 2025, with the low at 23559000.0 in Q4 2024.
  • Average Income from Continuing Operations over 4 years is 11412500.0, with a median of 11513000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 136.77% in 2024, then soared 77.49% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 11144000.0 in 2022, then grew by 10.71% to 9950000.0 in 2023, then crashed by 136.77% to 23559000.0 in 2024, then soared by 52.69% to 11146000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 11146000.0, 8212000.0, and 2067000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.